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Objective: A population-based point-prevalence study was conducted to determine the prevalence of peripheral arterial disease
(PAD) in Sweden, with special attention to critical limb ischemia and sex differences.
Methods: An age-standardized randomly selected population sample of 8000 women and men, aged 60 to 90 years, from four
different regions in Sweden was invited to participate. The sample had the same age and gender distribution as the Swedish
population in this age group. Participating subjects completed questionnaires on medical history, present medication, and
symptoms, and their ankle-brachial index (ABI) was measured. Subjects were analyzed for presence of PAD according to
reported symptoms and an ABI <0.9.
Results: A total of 5080 subjects were included, giving a participation rate of 64%. The prevalence of any PAD, asymptomatic
PAD, intermittent claudication, and severe limb ischemia was, respectively, 18% (95% confidence interval [CI], 16% to 20%)
11% (9% to 13%), 7% (6.5 to 7%) and 1.2% (1% to 1.5%). Women had a higher prevalence thanmen when PADwas diagnosed
with ABI only; that is, asymptomatic PAD (12.6% vs 9.4%, P .03) and severe limb ischemia (1.5% vs 0.8%, P< .008). The
prevalence of any PADwas 7.9% in the age group 60 to 65 years and increased to 47.2% among the age group 85 to 90 years.
Severe limb ischemia occurred in 0.3% in the youngest age group, was highest in the age group 80 to 84 years at 3.3%, and
declined to 2.5% among the oldest. The prevalence of PAD differed between regions (P < .0001).
Conclusions: PAD is common in Sweden, and almost a fifth of all elderly individuals have some stage of this disease. Women
are more often afflicted than men. The prevalence of severe ischemia, as a measure of critical limb ischemia, is about 1% the
population. (J Vasc Surg 2007;45:1185-91.)Peripheral arterial disease (PAD) is defined as atheroscle-
rosis in the arteries distal to the aortic bifurcation, with or
without symptoms in the legs. It is diagnosed by ankle-
brachial pressure index (ABI) measurements and symptoms,
and a confirmed diagnosis is associated with an increased
cardiovascular mortality reaching the same levels as in patients
with symptomatic coronary disease.1 To reduce this risk,
advice on lifestyle changes and exercise as well as pharmaco-
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doi:10.1016/j.jvs.2007.02.004logic treatment, including antiplatelet and statin therapy,
should be offered to patients.2-4 Symptomatic treatment is
indicated for PAD patients with significant symptoms, but its
use is highly variable between different parts of the world and
even within countries.
Previous populations-based prevalence estimations indi-
cate that a large proportion of Western populations has PAD,
but most studies were performed more than a decade ago. 5-7
Since then, changes in PAD prevalence may have occurred
because of the aging population, increased awareness of this
disease in the health care community, and improved risk factor
management, including smoking cessation.8-10 Such positive
developmentsmay differ among regions depending on imple-
mentations of health care programs.Moreover, little informa-
tion is available in the literature about sex differences in PAD
prevalence, and data on severe symptomatic forms of PAD are
entirely missing.11-13
Accurate and up-to-date information on PAD prevalence
is important to enable identification of groups in the popula-
tion where risk reduction and symptomatic treatment are
needed. This could facilitate better projection of the resources
needed and their allocation. The purpose of this study was to
determine the PAD prevalence in Sweden. In particular, we
aimed for identification of differences in prevalence between
genders. A secondary goal was to establish a population-based
prevalence of severe ischemia, as a measure of critical limb
ischemia (CLI), for the first time in the literature.
1185
JOURNAL OF VASCULAR SURGERY
June 20071186 Sigvant et alMATERIAL AND METHODS
Pilot study. A pilot study was performed in February
2004 to determine logistic factors influencing the final proto-
col and to estimate the sample size needed for themain study.
The goal set was to identify at least 400 subjects with symp-
tomatic PAD for later follow-up studies. The pilot study
included 53 subjects, aged 59 to 89 years, who were selected
at random from a population register. Of these, 33 (62%)
accepted the first invitation, and five (9%) were examined in
their homes, giving a participation rate of 72%. The mean age
 standard deviation the group was 72.3 7.8 years. Twelve
subjects (32%) with an ABI 0.9 were identified, and three
(8%) had symptomatic PAD. Timemanagement studies from
this pilot study were then used to calculate the resources
needed for the main study, and a cohort size of 8000 subjects
was chosen.
Population. The population of Sweden in 2004was 9.2
million. Seventeen percent were65 years old, and 10%were
born outside the country or had parents who were immi-
grants.14 To cover demographic and geographic distributions
in the Swedish population, four separate regions in the coun-
try were selected for the study. A random sample from these
regions with the same age and gender distribution as the
Swedish population in this age group, consisting of 2000
subjects from each region, was extracted from the govern-
ment’s tax register in June 2004. The age interval usedwas 60
to 90 years. The subjects were selected by residence and,
thereby, use of health care centers (HCs). Seven HCs were
involved to cover the population. In Malmö, representing a
southern andurban community,RosengardHCwas enrolled.
This HC covers a population with 59% immigrants, mainly
from Yugoslavia and Iraq. The other HCs were Karlstad, a
western urban community; Skutskär, an eastern rural and
industrial community; and Skellefteå region covering a north-
ern rural and agriculture district. Very few immigrants lived in
the latter three regions. In the southern region, twoHCswere
used for logistic and practical reasons. In the northern region,
three HCs were included because each covered only small
populations.
Ethical approval. The study was approved by the local
ethics committees in Stockholm (KI 03-538), Umeå Univer-
sity (Dnr 03-459), Lunds University (Dnr 832-0), Uppsala
University (Dnr 03-564), and Örebro (Dnr 374- 03). In-
formed consent was obtained from each participant.
Data collection. The subjects were invited to partici-
pate in the study by a letter. Enclosed with the invitation were
three self-administered questionnaires, which were translated
into languages other than Swedish when needed. One ques-
tionnaire assessed the presence of risk factors, such as diabetes
mellitus, hypertension, coronary heart disease, cerebrovascu-
lar disease, and renal failure and included current and former
smoking habits. It also covered the Rose’s World Health
Organization (WHO) questionnaire questions and leg symp-
toms.15 Another covered present use and duration of any
pharmacologic treatment, and the third was a validated walk-
ing impairment questionnaire.16,17 Analyses of questionnaire
data for risk factors, pharmacologic treatment, and walkingimpairment have not yet been performed and therefore are
not presented in this report.
The participants were invited to the HC, and house calls
were made when requested. Specially trained nurses per-
formed ABI measurements, checked the quality of the ques-
tionnaire answers, and assisted if they were incomplete. The
study lasted about 8 weeks at each site, and for the entire
study, 12 nurses were trained and employed. Before starting
the trial, each nurse was required to pass a theoretical and
practical test evaluating PAD knowledge and the ABI mea-
surement technique. A coordinating research nurse visited
each HC at least twice during the assessment period to mon-
itor and validate the examination procedure and data record-
ing.
ABI was determined by measuring the blood pressure at
the right arm using a 12-cm-wide BP cuff with the patient in
a sitting position. The ankle blood pressure was measured
using a pocket CW-Doppler (8-MHz Doppler-probe,
Hadeco, Sweden) and the same blood pressure cuff. These
measurements were performed twice in each leg with the
subject in supine position by insonating both the posterior
tibial and dorsal pedal arteries. One specific nurse in each
region entered the recorded data into an Access database
(Microsoft Inc, Redmond, Wash).
Subjects who were considered at risk for severe ischemia
or who had a high blood pressure (180 mm Hg) were
referred to their general practitioners, but no other interven-
tions were made during the assessment period.
Diagnosis criteria and definitions. ABI was defined
as the ratio of the lowest systolic blood pressure in the ankle
divided by systolic blood pressure in the arm, as suggested
in the literature.18 The rationale for using the lowest ankle
blood pressure was to make sure that subjects with gener-
alized arteriosclerosis were included in the definition of
asymptomatic PAD because this group is associated with a
high risk for cardiovascular events. The definitions used for
analysis of the data collected are listed in Table I. Severe
ischemia-2 (SI-2) was used to improve prevalence estima-
tion of CLI and to complement SI-1 by covering the most
common definitions of CLI—having an ankle pressure
70 mm Hg and rest pain.13 The second part of the CLI
definition concerning ulcer and gangrene manifestation
was not included in the questionnaires or examinations in
this study. We also used a third CLI criteria (SI-3) that
constituted all subjects with an ankle pressure50mmHg.
Incompressible vessels, as a sign of PAD, was defined as an
ABI 1.4.13
Statistical analysis. Because the distribution of age was
skewed, theMann-WhitneyU test was used for comparison of
the median between participants and nonparticipants. For
analyses of frequencies, the Fisher exact test and 2 test were
used. The 2 test was also used for comparison of prevalence
between regions. Adjustment for age, sex, and participation
rate was performed for this analysis and had no influence in
prevalence. The test of equal proportions was used to analyze
gender differences in prevalence, accounting for sample de-
sign and participating rate.
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cohort of patients was small and therefore results were consid-
ered unreliable.
All statistical analyses were performed using SPSS 12.0
software (SPSS Inc, Chicago, Ill). Values of P  .05 were
considered statistically significant, and data were presented
as median and interquartile range (IQR) for age and per-
centages with 95% confidence intervals (CI) for prevalence.
RESULTS
Study population. Of the 8000 invited persons, 5080
agreed to participate. This gave a response rate of 64%. There
were 2779women (55%) and2301men (45%),with amedian
age of 71 (IQR, 13 years). The participation rate differed with
age. It was lowest (40%) in the oldest age group of 80 to 90
years and highest (70%) among those aged 60 to 70 years.
Characteristics of nonparticipators. There were sig-
nificantly fewer participating subjects in Malmö (44%; P 
.001) compared with the other regions: A¨lvkarleby had 65%,
Skellefteå region had 74%, and Karlstad had 70%. Those
choosing not to participate were a median age of 74 years
(IQR, 16 years), which was significantly higher than in the
study group (P .001). Significantly more women thanmen
decided not to participate (1702 vs 1213, P  .001). The
reason for not participating given by 1488 subjects in response
to the study invitation letter is given in Table II.
For further characterization, 262 subjects were randomly
selected from the entire group of nonparticipators and were
Table I. Definitions of peripheral arterial disease used for
Nomenclature
1. Peripheral arterial disease (PAD) All subjects with an
2. Asymptomatic PAD (APAD) Subjects with an AB
the calf or thigh w
3. Intermittent claudication (IC) Subjects with an AB
thigh when walkin
4. Severe ischemia-1 (SI-1) All subjects with an
5. Severe ischemia 2 (SI-2) All subjects with ank
This was defined a
ABI, Ankle-brachial index.
Table II. Reasons given in response to the invitation
letter for not participating in the study.
Reason N (%)
Dead 51 (4)
Moved out of the area 17 (1)
Alzheimer’s disease 98 (7)
Terminal disease 115 (8)
Perceived themselves as healthy 26 (2)
Do not want to 809 (54)
No contact 79 (4)
Other reasons* 292 (20)
Total 1488 (100)
*Other reasons include: gone on holiday, busy working, do not have the
time, too tired, taking care of a sick relative.interviewed by telephone. The results are given in Table III.These subjects were also asked to respond to the questions in
Rose’s WHO questionnaire, and 18 (7%) gave a positive
answer according to the intermittent claudication (IC) defini-
tion; 92 (35%) did not. Most of this group, 152 (58%),
preferred to not answer this question.
Prevalence. According to definition 1, 18% (95% CI,
16.0 to 19.9) of the study population had any type of PAD,
and 566 subjects were asymptomatic as established by defini-
tion 2 (Table IV). IC according to definition 3 was present in
340 subjects, whereas 61 had SI-1 according to definition 4.
According to definition 5, 20 subjects (0.4%) had SI-2, and
the prevalence for SI-3 was 0.33% in the total population
(0.54% among women, 0.07% among men). The ABI was
1.4 in 12 subjects (7 men, 5 women).
Sex differences. Fig 1 displays the prevalence figures in
relation to the age of the participants by sex. Asymptomatic
PAD was more frequent among women (P .03) than men.
SI-1 (P .008) and SI-2 (no statical analysis performed)were
also more common among women. This pattern was consis-
tent for all age groups. IC prevalence tended (P .09) to be
more common among men overall. For the oldest age group
and for subjects aged 75 to 79 years, IC had a higher preva-
lence among men.
Regional differences. Regional prevalence is presented
in Fig 2. The prevalence of PAD was 22% in Karl-
stad, which was significantly (P .0001) higher than in other
sis of the collected data
Definition
0.9 with or without symptoms.
9 without qualifying answers in the questionnaire (ie, no pain in
alking).
9 and qualifying answers in questionnaire (ie, pain in calf or
pressure 70 mm Hg.
ssure 70 mm Hg and a qualifying answer in the questionnaire.
in the leg at rest.
Table III. Reasons given by randomly selected
nonparticipators at telephone interviews for not
participating in the study.
Reason N (%)
Dead 18 (7)
Moved out of the area 3 (1)
Alzheimer’s disease 14 (5)
Terminal disease 18 (7)
Perceived themselves as
healthy
11 (4)
Do not want to 55 (21)
No contact 29 (11)
Other reasons* 114 (44)
Total 262 (100)
*Other reasons include: gone on holiday, busy working, do not have the
time, too tired, taking care of a sick relative.analy
ABI 
I 0.
hen w
I 0.
g).
ankle
le pre
s painregions, as was the prevalence of asymptomatic PAD (15%, P
rtions.
is no
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in Malmö. This region demonstrated a slight dominance for
IC compared with asymptomatic PAD (8.4% vs 7.8%). The
highest prevalence of SI-1, 2.2%, was found in A¨lvkarleby,
were it was more common (P  .008) than in the other
regions.
DISCUSSION
Two findings in this study support the previous litera-
ture on the subject. PAD is very common in older age
groups and most subjects with this disease are asymptom-
atic. The present study also reveals some more unique
observations. The first is that women dominate among
Table IV. Peripheral arterial disease prevalence by gender
Stage of PAD
Peripheral arterial disease (all with ABI 0.9)
Asymptomatic PAD (all with ABI 0.9 without symptoms)
Intermittent claudication (all with ABI 0.9 and positive Rose Q
Severe ischemia 1 (all with ankle BP 70 mm Hg)
Severe ischemia 2‡ (all with ankle BP 70 mm Hg and rest pain)
PAD, Peripheral arterial disease; ABI, ankle-brachial index.
*Data presented as percentage (95% confidence interval).
†Comparing prevalences among women and men with test of equals propo
‡No comparisons performed for severe ischemia-2 due to a small cohort.
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A
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40
60-64 65-69 70-74 75-79 80-84 85-90
C
Prevalence (%)
Fig 1. Prevalence of peripheral arterial disease (PAD)
presented with 95% confidence intervals (CIs).A,All PAD
D, Severe ischemia based on ankle pressure only (the CIthose with PAD when the definition is based only on ABI,the second is that the prevalence differs between geo-
graphic regions, and finally, that the prevalence of severe
ischemia, as measure of CLI, seems to be present in almost
1% of the population over 60 years old.
The overall prevalence of PAD of 18% in our study is in
the same range as in other population-based point-prevalence
studies, especially when compared with data that are based on
similar age groups and study design.5-7 Although the assess-
ment periods for these three studies are dispersed over a
10-year period, the prevalence figures reported were very
similar to the present study. For instance, almost identical
overall prevalences were found in the Rotterdam study,7 sug-
gesting a rather constant occurrence of PAD over time. Ac-
stage of disease*
Total Women Men P†
8.0 (16.0-19.9) 19.2 (15.9-22.4) 16.5 (15.8-18.4) .112
1.1 (9.5-12.8) 12.6 (9.7-15.4) 9.4 (8.8-9.9) .03
6.8 (6.5-7.1) 6.6 (6.1-7.1) 7.1 (6.9-7.3) .092
1.2 (1.0-1.4) 1.5 (1.1-1.9) 0.83 (0.6-1.1) .001
0.4 0.6 0.1
60-64 65-69 70-74 75-79 80-84 85-90
B
valence (%)
5
10
15
20
25
60-64 65-69 70-74 75-79 80-84 85-90
Prevalence (%) 
D
fic to age and sex (women, filled bars; men, open bars)
es.B,Asymptomatic PAD.C, Intermittent claudication.
t displayed because of small cohorts).and
1
1
)10
20
30
40
50
60
Pre
speci
stagcordingly, the PAD prevalence remains the same despite a
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management for atherosclerosis during this time period.19,20
This observation is contradicted by the data from Fowkes
et al5 published in 1991, who determined the prevalence for
PAD, asymptomatic PAD, and IC to 16.6%, 8%, and 4.5%,
respectively. Although also presenting similar data, the inves-
tigated population was substantially younger (55 to 74 years)
in that study. Comparing our data for this age group with the
findings by Fowkes et al findings indicates a decline in PAD
prevalence over time. Variations in risk factor burden, study
design, and dissimilarities between countries or between eth-
nic groups could be other plausible explanations for this
difference.21 The overall prevalence found in this study was
also similar to more recent data that did not use a population-
based selection of study participators.22,23
Previous prevalence data on IC vary greatly in the litera-
ture and range from 1% to 14 %.24-27 It is noteworthy that no
IC prevalence studies have been performed in the last decade
to our knowledge, and only a few of the previous ones in-
cludedwomen.The variation in ICprevalence is likely tobe an
effect of problems using subjective symptoms for diagnosis in
addition to differences in study design. Our IC prevalence of
7% is higher, in particular among women, than in the compa-
0
5
10
15
20
25
30
Karlstad Skellefteå
Prevalence (%)
Fig 2. Prevalence of peripheral arterial disease (PAD
percentages and 95% confidence intervals.rable Rotterdam study, which also used questionnaire dataand an ABI 0.9 to establish the diagnosis.7 It is also much
higher than in a study from North America.28 Because of the
similarities in study design, these discrepancies probably re-
flect a true high IC prevalence among Swedish women.
Our prevalence data on SI are, to our knowledge, the first
to be recorded using population-based identification of co-
horts. The prevalence of 1.2% when based on70mmHg in
ankle blood pressure and 0.5% when adding symptoms is in
the vicinity of data extrapolated from registers of vascular
interventions for CLI.13,29 Basing the presence of SI on an
ankle blood pressure50mmHg also indicated a prevalence
of about 0.5%.
It can be argued that our SI definitions are not equivalent
to the definitions of CLI used in the TransAtlantic Inter-
Society Consensus (TASC) document. As discussed subse-
quently, we encountered several problems when trying to
estimate this prevalence and decided to use two definitions to
cover asmuch of it as possible. It is possible, however, that the
SI prevalence is underestimated in this study. We may have
identified more subjects with SI with a higher participation
rate in the group 80 years, where SI was most prevalent.
This is suggested by the decline in SI prevalence in the oldest
age group, 85 to 90 years, which had the highest nonpartici-
Malmö Älvkarleby
All PAD
Asymtomatic PAD
Intermittent claudication
Severe ischemia
ges separated by geographic regions is presented in) stapation rate. The most common reasons given for nonpartici-
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further support this interpretation.
Estimating the number of patients with SI in Sweden
from our data suggests that up to 15,000 subjects had CLI in
2004 (1% of the Swedish population over 60 years old).
Comparing this figure with 1700 interventions for CLI in the
Swedish Vascular Registry the same year suggests that too few
patients underwent vascular reconstruction for symptomatic
relief. Using our prevalence data and the estimated number of
persons over 60 years old from the United States Census
Bureau data from 1999 (50 million), we conclude that about
500,000 persons in the United States may have CLI.
Determining PAD prevalence is associated with problems
with ABI measurements and the reporting of symptoms. ABI
is generally accepted as valid tool to diagnose PAD,30 and an
ABI 0.9 has a 95% to 98% specificity and 90% sensitivity in
detecting the symptomatic forms of PAD when angiography
findings are used as the gold standard.31,32 The interobserver
variability is reported to be 11%.33 In this study, we tried to
minimize this variability by havingworkshops inmeasurement
techniques, including skill tests, for the nurses performing the
measurements. We also used closed monitoring throughout
the study period. Accordingly, we believe that the prevalence
figures based on ABI are valid and comparable with data in
other reports.
Determining the prevalence of IC and SI-2 requires an
addition of symptoms to the ABI and thus the diagnosis is
more uncertain. Walking problems are difficult to assess in
questionnaires, and separating IC from other walking disabil-
ities is almost impossible. In most previous studies Rose’s
WHO questionnaire has been used, with a specificity of 80%
to 90% but a sensitivity of only 50% for detecting PAD
diagnosed by a treadmill test.27 Also for SI, the reported
symptoms are difficult to interpret.
According to the CLI definitions by the TASC group,
manifest rest pain or ulcers should be added to the objective
assessment of ankle blood pressure.13 Unfortunately, rest pain
symptoms depend on pain perception, which in turn is influ-
enced by neuropathy. They could also be influenced by anal-
gesics.
In addition, arterial ulcers can be of venous or inflamma-
tory etiology and they can be located in the distal calf.34
Whether such ulcers should be included when defining and
assessing SI can be questioned, andwe found it almost impos-
sible to define ulcers with a predominately arterial etiology in
a standardized way. The problems with this assessment were
the reason for using the nomenclature SI instead ofCLI in this
study.
Women dominated both types of PAD determined by
ABI in our study as they did in the National Health and
Nutrition Examination Survey.23 Constitutionally higher ABI
inwomen, smoking habits, postmenopausal hormonal effects,
lower prescription rates of drugs to reduce risk factors, and
smaller vessels could be possible explanations for this differ-
ence between men and women.35-37 As mentioned, studies
focusing on IC have often reported a higher prevalence
among men.27,38 The reason for the discrepancy between
these studies and ours may be differences in study design suchas diagnostic criteria or an increase in female IC prevalence
over time. Questionnaire data may also underreport IC in
women because women experience walking problems differ-
ently from men.39 They are also less likely to report symptoms
owing to a lower level of physical activity.11 Of interest in our
study was that the PAD prevalence figures differed most
among the genders in the oldest age group. This difference in
absolute points in our studywas 8%higher inmen for IC,who
in turn had 3% lower SI prevalence. This may be a conse-
quence of the mentioned difference in walking habits and a
general higher morbidity in women.
The overall prevalence of PAD was significantly higher in
theKarlstad region comparedwith the other areas. Cardiovas-
cular mortality has previously been studied in the counties of
Sweden and an east-western regional gradient of cardiovascu-
lar mortality was found, with Karlstad in the area with the
highest mortality.40 Nerbrand et al40 could not identify vari-
ations in risk factors alone as an explanation for this; instead,
they suggested drinking water hardness was an important
factor influencing mortality.40 SI was prominent in the
A¨lvkarleby region. This area has a large proportion of second-
generation immigrants from eastern Finland with a high car-
diovascularmorbidity, and it is probable that the smoking rate
in this area also is high. The inhabitants in Rosengård dis-
played a slightly higher prevalence of IC compared with the
other regions, but PAD occurrence in general was similar.
Ethnic and cultural differences in walking impairment percep-
tion may be an explanation for this.41,42
CONCLUSION
PAD is very common among elderly individuals, and the
prevalence differs between regions. Women more often have
asymptomatic PAD and SI thanmen. The explanation of why
women have a similar prevalence of IC as men may be a
consequence of the need for using the subjective perceptionof
walking problems to obtain the diagnosis. The prevalence of
SI is likely to be in the area of 0.5% to 1.2 %, but may be
underestimated in this study owing to a large proportion of
nonparticipators in the oldest age group, where SI was most
common.
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